chevron_leftBack
As of 17 June 2026, Cambium Bio Ltd. has a market cap of $8.7M USD, ranking #42047 globally and #1374 in Australia.
It ranks #3726 in the Healthcare sector, and #733 in the Biotechnology industry.
Key Stats
Market Cap
$8.7MUSD
12.3M AUD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Karolis Rosickas
open_in_new
Founded
2013
Website
cambium.bio
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -6.7% | -2.2% | -6.2% | -25% | -7.2% | 55% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
CMB
Cambium Bio Ltd
ISIN: AU0000327769
Shares Out.:
Shares Outstanding:
27.332M1
Shares Float:
26.508M2
|
0.4200 AUD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Cambium Bio Ltd.
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
ASX: CSL
|
$42.64B
490K%
60.27B AUD
|
29.3
|
|
ASX: TLX
|
$3.6B
41K%
5.09B AUD
|
-
|
|
ASX: MSB
|
$2.04B
23K%
2.88B AUD
|
-
|
|
ASX: PNV
|
$493.62M
6K%
697.75M AUD
|
71.8
|
|
NASDAQ: KZIA
|
$141.64M
2K%
|
-
|
|
ASX: IMM
|
$65.68M
655%
92.84M AUD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
2M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
2M%
|
19.0
|
|
EBR: ARGX
|
$47.99B
551K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$45.02B
517K%
68.19T KRW
|
35.5
|
|
SIX: LONN
|
$42.46B
488K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.23B
324K%
42.76T KRW
|
43.8
|
chevron_leftBack